Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Eye Care Evolution | Alcon navigates a competitive landscape while leveraging its robust product pipeline, balancing challenges and opportunities in the global eye care market. |
Financial Resilience | Despite mixed Q2 2024 results, Alcon demonstrates strong operational efficiency with margins exceeding expectations. EPS projections indicate steady growth. |
Competitive Dynamics | Explore how Alcon faces pressure from established players and innovative newcomers, potentially impacting its dominant position in the U.S. PC-IOL market. |
Growth on the Horizon | Discover Alcon's multi-year upgrade cycle, including new surgical systems, glaucoma treatments, and expansion in China, with price targets ranging from $95 to $110. |
Metrics to compare | ALC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALCPeersSector | |
---|---|---|---|---|
P/E Ratio | 37.7x | 5.6x | −0.4x | |
PEG Ratio | 5.68 | 0.25 | 0.00 | |
Price/Book | 1.9x | 2.4x | 2.6x | |
Price / LTM Sales | 4.3x | 2.8x | 3.0x | |
Upside (Analyst Target) | 24.8% | 22.1% | 52.3% | |
Fair Value Upside | Unlock | 10.0% | 9.4% | Unlock |